~~<i id='04DFC1F2AF'><strike id='04DFC1F2AF'><tt id='04DFC1F2AF'><pre id='04DFC1F2AF'></pre></tt></strike></i>~~

Home» focus» focus

focus

author：focus 2025-09-29 16:24:26 Page View：623

Hiram Secrist (left), who has Duchenne muscular dystrophy, with his mother, Kristen Secrist (center), and his grandmother, Terrie Jordan. Courtesy Secrist family

In mid-July, Kristen Secrist hopped on a call with her 5-year-old son’s doctor, who had urgent news: The first gene therapy had been approved for Duchenne muscular dystrophy. Her son, Hiram, would be a perfect candidate — if, she added, they could get him dosed in time.

The treatment was approved only for 4- and 5-year-olds. Hiram turned 6 in three weeks.

“Oh, crap,” Secrist said to herself.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： In same hospitals, Black patients receive fewer opioids than white patients
Next article： Novavax promises a turnaround & Lilly roils the obesity market

leisure time

Duchenne breakthrough therapy leaves behind pioneering families

DuchennemusculardystrophyDr.EdwinP.Ewing,Jr./CDCPatFurlongwassittinginherhomeofficeinMiddletown,Ohio

Shkreli is convicted of fraud. Can pharma finally slam the door on him?

KevinHagen/GettyImagesIsthistheendofthelineforthe“pharmabro”withtheperpetualsmirk?MartinSkhreliwasfo

Moonlake's readout produced a cash windfall. Risks remain

MollyFerguson/STATFortwodaysstartingonSunday,MoonlakeImmunotherapeuticshappilycrunchednumbersandshar

For Cytokinetics, FDA rejection of heart drug would help, not hinder

MollyFerguson/STATCytokineticswasfounded26yearsagobuthasnotyetdevelopedadrugsuccessfullytoapproval.T